Post by Gilead Sciences

#InTheNews: Yesterday, we received FDA approval for our treatment for first-line metastatic triple-negative breast cancer (mTNBC). Read recent coverage highlighting the impact of this approval and our steadfast commitment to driving innovation in cancer care: https://gilead.inc/4aliqp2